Review
Oncology
Jianyun Jiang, Hongmei Ying
Summary: This paper reviews the mechanisms by which nasopharyngeal carcinoma cells evade immune surveillance and the methods attempted to restore immunity. Chronic Epstein-Barr virus infection is found to be the most common causative agent in nasopharyngeal carcinoma.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Immunology
Liping Wang, Dujuan Wang, Liu Yang, Xiaojiao Zeng, Qian Zhang, Guohong Liu, Yunbao Pan
Summary: This study focused on the roles of cuproptosis-related genes and Jab1 in the tumor microenvironment of nasopharyngeal carcinoma (NPC) and head and neck squamous cell carcinoma (HNSCC). The expression of these genes differed between the tumor cell enriched region and the immune cell enriched region. In HNSCC patients, higher expression of ATP7A, DBT, DLD, and LIAS was associated with better prognosis in the high Jab1 group, while higher expression of these genes was associated with worse prognosis in the low Jab1 group. These findings provide a basis for targeted therapy and drug development.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Xinya Tong, Yilan Xiang, Yuanbo Hu, Yingying Hu, He Li, Huilin Wang, Kong-Nan Zhao, Xiangyang Xue, Shanli Zhu
Summary: The study revealed that NSUN2 is upregulated in NPC and enhances proliferation, migration, and invasion of NPC cells in vitro. Differential expression genes are mainly related to activation and proliferation of multiple immune cells.
FRONTIERS IN ONCOLOGY
(2022)
Article
Engineering, Biomedical
Shupei Tang, Lan Zhou, Haiyang He, Liwei Cui, Zhicheng Ren, Yuhang Tai, Zhunyi Xie, Yi Cao, Dongwei Meng, Qiuli Liu, Yuzhang Wu, Jun Jiang, Xinyuan Zhou
Summary: This study developed a novel cancer vaccine that effectively enhances the immune response against tumor cells in the tumor microenvironment. The vaccine activates immune cells, boosts the production of tumor-specific T cells and pro-inflammatory cytokines, and suppresses tumor growth and metastasis.
Article
Oncology
Ya-Qin Wang, Xu Liu, Cheng Xu, Wei Jiang, Shuo-Yu Xu, Yu Zhang, Ye Lin Liang, Jun-Yan Li, Qian Li, Yu-Pei Chen, Yin Zhao, Jing-Ping Yun, Na Liu, Ying-Qin Li, Jun Ma
Summary: This study aimed to quantify the spatial heterogeneity of lymphocytes and cancer cells in the tumor microenvironment of NPC patients and evaluated its prognostic value. The results demonstrated that immune hotspot scores were associated with better clinical outcomes, while further investigation on spatial variation is needed for a comprehensive understanding.
Article
Immunology
Zihan Zhao, Siyang Liu, Rui Sun, Wenjie Zhu, Yulin Zhang, Tianyao Liu, Tianhang Li, Ning Jiang, Hongqian Guo, Rong Yang
Summary: Bladder cancer is a highly malignant tumor with limited improvement in prognosis and survival rates. Immune checkpoint inhibitors have revolutionized the treatment of bladder cancer, but their clinical application is limited by low response rates. This study investigated the combination of oxaliplatin and anti-PD-1 inhibitor in bladder cancer mouse models and found that this combination therapy was more efficient than medication alone.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Nan Xiao, Xiaodong Zhu, Kangshuai Li, Yifan Chen, Xuefeng Liu, Bin Xu, Ming Lei, Jiejie Xu, Hui-Chuan Sun
Summary: This study found that Siglec-10(hi) TAMs in HCC patients are associated with immune suppression and poor prognosis. Blocking Siglec-10 can enhance the anti-tumor effects of CD8(+) T cells and improve the efficacy of PD-1 inhibitors.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Craig L. Slingluff, Hassane M. Zarour, Hussein Abdul-Hassan Tawbi, John M. Kirkwood, Michael A. Postow, Philip Friedlander, Craig E. Devoe, Elizabeth M. Gaughan, Ileana S. Mauldin, Walter C. Olson, Kelly T. Smith, Mary J. Macri, Toni Ricciardi, Aileen Ryan, Ralph Venhaus, Jedd D. Wolchok
Summary: Treatment with IPI + NY-ESO-1 vaccines enhanced T cell and antibody responses in patients. Patients with best clinical responses had broader antibody responses and increased T cell densities.
Review
Immunology
Xiaojing Yang, Hanru Ren, Zhen Li, Xue Peng, Jie Fu
Summary: This article summarizes the application of immunotherapy in NPC, with a focus on the use of immunotherapy and radiotherapy in the treatment of NPC.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Liu Yang, Guohong Liu, Yirong Li, Yunbao Pan
Summary: The clinical study of nasopharyngeal carcinoma has shown that tumor-infiltrating lymphocytes (TILs) play a significant role in the development and prognosis of the disease. Recent research has demonstrated the predictive value of TILs subsets for NPC patients and the success of adoptive immunotherapy using anti-tumor TILs. This review evaluates the role of TILs in tumor growth and explores the potential benefits of TILs-based immunotherapy in NPC treatment.
Article
Immunology
Wangzhong Li, Shuhui Lv, Guoying Liu, Nian Lu, Yaofei Jiang, Hu Liang, Weixiong Xia, Yanqun Xiang, Changqing Xie, Jianxing He
Summary: We have revealed the distinct cellular composition and functional characteristics of EBV DNA seropositive and seronegative nasopharyngeal carcinoma (NPC) patients at the single-cell level. EBV DNA seropositive tumor cells show lower differentiation potential, stronger stemness signature, and upregulated signaling pathways associated with cancer hallmarks. Transcriptional heterogeneity and dynamics in T cells are associated with EBV DNA seropositivity, indicating different immunoinhibitory mechanisms employed by malignant cells. EBV DNA seropositive NPC forms a specific immune context characterized by low expression of classical immune checkpoints, early-triggered cytotoxic T-lymphocyte response, global activation of IFN-mediated signatures, and enhanced cell-cell interplays.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Yihe Yan, Leting Zheng, Qiang Du, Hamza Yazdani, Kun Dong, Yarong Guo, David A. Geller
Summary: IRF-1 regulates anti-tumor immunity in HCC by modulating CXCL10 and CXCR3, inhibiting proliferation and promoting apoptosis. It overcomes proliferation partly through activating the CXCL10/CXCR3 autocrine axis.
Article
Cell Biology
Ester Fagnano, Swati Pendharkar, Madyson Colton, Philip N. Jones, Marta Crespi Sallan, Tetyana Klymenko, Andrejs Braun, Christian Klein, Jamie Honeychurch, Eleanor J. Cheadle, Timothy M. Illidge
Summary: This study showed that contact between tumor cells and stromal cells inhibits the effector functions of Obinutuzumab, highlighting the potential for improved therapies targeting the microenvironment to enhance patient outcomes in B-cell malignancies.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Huihuang Li, Jinbo Chen, Zhenghao Li, Minfeng Chen, Zhenyu Ou, Miao Mo, Ruizhe Wang, Shiyu Tong, Peihua Liu, Zhiyong Cai, Chunyu Zhang, Zhi Liu, Dingshan Deng, Jinhui Liu, Chunliang Cheng, Jiao Hu, Xiongbing Zu
Summary: A systematic multi-omics analysis identified S100A5 as a novel immunosuppressive target for bladder cancer. The expression of S100A5 inhibits CD8(+) T cell recruitment and cytotoxicity, leading to resistance to immune checkpoint blockade therapy. Targeting S100A5 enhances the infiltration and cytotoxicity of CD8(+) T cells, thereby enhancing the efficacy of immune checkpoint blockade therapy in bladder cancer.
Article
Immunology
Mou Peng
Summary: This study aimed to classify immune subtypes and investigate the tumor microenvironment of urothelial carcinoma to improve the understanding and response of immunotherapy. Patients were classified into four immune subtypes with different molecular expression, immune cell infiltration, and clinical characteristics. The C3 immune subtype displayed abundant immune cell infiltrations and hot tumor phenotypes, while the C4 immune subtype had few immune cell infiltrations and cold tumor phenotypes. C3 subtype showed higher expression of tumor mutation burden, inhibitory immune checkpoints, and immunogenic cell death modulators. Patients with the C4 subtype had a better overall survival probability. TGFB3 was identified as a potential biomarker for predicting immunotherapy resistance. This study provides a bioinformatics basis for understanding the immune landscape of urothelial carcinoma.
FRONTIERS IN IMMUNOLOGY
(2022)